Keywords: Pfizer, Biocon, Biosimilars, Insulin, Novo Nordisk

Pfizer and Biocon cancel biosimilars deal

Article | 14 March 2012

Print This

Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced that they have called off their ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in